Join Forte Biosciences for a virtual R&D Day on the development of FB102 across autoimmune indications. The event will feature key thought leaders in celiac disease, vitiligo, and alopecia areata including:

• Prof. Jason Tye-Din, MD, PhD, Head of Celiac Research at the Walter and Eliza Hall Institute
• Prof. Christopher Ma, MD, MPH, FRCPC, academic gastroenterologist at the Cumming School of Medicine, University of Calgary
• Prof. David Rosmarin, MD, Chair of the Department of Dermatology at the School of Medicine, Indiana University

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.

A live question and answer session will follow the formal presentations.